If your oncologist mentioned the Stupp protocol, you likely have a new diagnosis of glioblastoma (GBM) or another high-grade glioma. It's scary, and the name doesn't help - it sounds confusing but actually has a clear structure. There are three connected phases after surgery. Knowing what happens during each one - the treatment itself, what your blood tests measure, and how long it takes - helps you ask better questions and plan your life around treatment.
What is the Stupp Protocol?
The Stupp protocol remains the standard way to treat glioblastoma after surgery. It combines radiation therapy with temozolomide chemotherapy given at the same time for roughly six weeks (the concurrent phase), then higher-dose temozolomide in monthly cycles for about six months (the adjuvant phase). Both aim to kill any remaining tumor cells and slow regrowth after surgery.
How a 2005 Trial Changed Everything
Before 2005, doctors used radiation alone after glioblastoma surgery. A large trial run by the European Organisation for Research and Treatment of Cancer (EORTC) and the Canadian National Cancer Institute compared radiation alone with radiation plus temozolomide. Real-world analyses of the Stupp regimen a decade after publication confirm the original finding: median overall survival improved from 12.1 months with radiation alone to 14.6 months with both treatments, and the two-year survival rate rose from 10.4 percent to 26.5 percent.
Those numbers show what happened on average across many people, not what will happen to any one person. Molecular markers, extent of surgical removal, age, and general health all shape how an individual responds. Doctors adopted this protocol as standard care because it was the first regimen that clearly helped patients in a large trial. The American Brain Tumor Association's overview of GBM treatment reflects this consensus: the Stupp protocol remains the foundation on which all newly diagnosed GBM treatment is built.
Phase Zero - Surgery Before Treatment Starts
The Stupp protocol starts after surgery. The goal of surgery is to remove as much tumor as safely possible. How much your surgeon removes matters - removing more tumor consistently leads to longer progression-free survival. This is why surgical technique, imaging guidance, and center expertise are central to your treatment plan.
After the operation comes a recovery period before chemoradiation starts. Most centers start chemoradiation within four to six weeks. How fast your wounds heal, how quickly you stop taking steroids, and how you feel all affect the timing. Some patients want to start immediately, but the protocol actually includes a recovery break on purpose.
Phase One - Concurrent Chemoradiation (About Six Weeks)
This is the first active treatment phase after surgery. You attend a radiation session five days a week for roughly six weeks - about 30 sessions total. The radiation covers the surgical cavity and a margin of surrounding tissue. The margin covers microscopic tumor spread that imaging can't always find.
At the same time, you take temozolomide as an oral capsule every day throughout the radiation period, including weekends. Doctors call this concurrent or concomitant treatment. Here's why they do it: temozolomide damages tumor DNA in a way that makes cells more vulnerable to radiation. The two work together more effectively than either would alone.
Common side effects during this phase include fatigue that builds gradually across the six weeks, mild to moderate nausea, hair thinning in the irradiated area, and headaches. Some patients notice changes in concentration, word-finding, or short-term memory. Understanding what causes cognitive changes during glioblastoma treatment - and which ones improve after radiation ends - helps you know what to expect.
One practical detail: because temozolomide suppresses the immune system, most oncologists prescribe a preventive antibiotic during the concurrent phase to reduce the risk of a lung infection called Pneumocystis jiroveci pneumonia (PCP). This is uncommon but serious in immunocompromised patients. Clinical analyses of patients receiving standard six-week chemoradiation confirm that antibiotic prophylaxis is a routine part of concurrent-phase management.
Your team checks your blood counts about every two weeks during this phase. They watch lymphocytes, platelets, and neutrophils. A significant drop might pause your treatment or require extra checks before you continue.
The Four-Week Window Between Phases
After six weeks of chemoradiation, you get a planned four-week break before the next phase. This break lets your bone marrow heal and gives you an MRI to see how the radiation worked.
That first scan comes about four weeks after chemoradiation ends and often confuses patients. Changes that look like tumor growth may actually be treatment-related inflammation. Doctors call this pseudoprogression. It happens often enough that most neuro-oncology teams expect it and have specific protocols for managing it. To learn how doctors tell pseudoprogression apart from true recurrence and why timing and repeat imaging matter, see the detailed explanation.
Phase Two - Adjuvant Temozolomide (Six Cycles)
The second active phase involves temozolomide taken in 28-day cycles. You take it on five days in a row, then stop for 23 days while your bone marrow recovers. Six cycles make up the standard course, spanning roughly six months. The dose is higher than during concurrent chemoradiation because you get it all at once in a short burst instead of spread out over many days.
Your team checks blood tests before each cycle to confirm counts have recovered enough to proceed. If your counts are too low, your team might delay the cycle by a couple weeks or lower the dose. Persistent lymphopenia (a lasting drop in lymphocytes) is one common reason to change the cycle, and it can make infections more likely even months later.
You might feel sick, tired, constipated, or get a mild rash during this phase. Many patients find this phase easier than the concurrent phase because treatment lasts five days per cycle instead of weeks straight. A systematic review of GBM management across the Stupp protocol era notes that patients who complete the full course tend to do better, and that dose changes in response to blood counts are routine.
Does Your MGMT Status Change What to Expect?
MGMT (O6-methylguanine-DNA methyltransferase) is an enzyme that helps tumor cells repair the type of DNA damage that temozolomide causes. When the MGMT gene is off (called methylated), tumor cells can't repair themselves efficiently, and temozolomide tends to work better. About 45 percent of newly diagnosed GBM patients have a methylated MGMT promoter. This group gets the strongest benefit from combining chemoradiation.
For patients with an unmethylated MGMT promoter, the Stupp protocol remains standard care, but temozolomide helps less. This means your full molecular profile - your MGMT status and other markers alongside the GBM diagnosis - matters before treatment starts. You can learn what those test results mean in what your glioblastoma pathology report really means.
If the pathology came from a center without neuro-oncology specialists, or if the MGMT result was unclear, getting a second opinion before you start treatment is smart. You can have the pathology and MRI reviewed by the Art of Healing Cancer team to clarify what the molecular findings mean for you before your first treatment session.
What About Tumor Treating Fields?
Since 2015, doctors have used a device called Tumor Treating Fields (TTFields, brand name Optune) alongside the adjuvant phase of the Stupp protocol for newly diagnosed glioblastoma. It sends low-intensity alternating electric fields to your scalp through adhesive arrays you wear on a shaved head. A large trial called EF-14 showed that adding TTFields to adjuvant temozolomide extended median overall survival compared to adjuvant temozolomide alone. Research into GBM treatment with TTFields shows that patients who wear the device at least 18 hours a day do better, which means wearing it every day is key to how well it works.
TTFields availability varies by country and treatment center. The device requires a shaved scalp and disciplined daily use. Access, cost, and whether you can use it daily all matter for whether TTFields makes sense for you. Your oncologist can review whether you're a good candidate and show you how to get the device.
Managing Side Effects Across Both Phases
Side effects depend on the phase, your individual response, and whether you're also taking other medications like dexamethasone (a steroid that reduces brain swelling). Dexamethasone has its own side effects - high blood sugar, sleep problems, mood changes - so your doctor lowers the dose to the minimum as soon as possible.
Fatigue is the symptom people report most often in both phases. It typically peaks in the final weeks of concurrent chemoradiation and may persist into the early adjuvant cycles before gradually improving. Rest when you need to, protect your sleep, and adjust your plans around treatment days. Gentle physical activity can help with treatment-related fatigue.
Nausea is most common in the first one or two days of each adjuvant cycle. Your doctor will give you anti-nausea medication with temozolomide, and it works best if you take it before the dose.
Immune suppression - especially low lymphocyte counts - can linger beyond the end of active treatment. Report any fever to your oncology team right away, on the same day it happens. Infections that would be minor in a healthy person can escalate more quickly when immune function is reduced. Most neuro-oncology teams provide a direct contact number for exactly this situation. Use it.
Your team checks your liver enzymes regularly during treatment because temozolomide can rarely raise them. These are part of your regular blood tests. Going to all your appointments is how you stay safe on the protocol.
If you're choosing a treatment center or want a second opinion on how the Stupp protocol applies to you, you can upload your MRI and pathology reports to the Glioblastoma Center for a remote case review before your treatment starts.
When to Talk to Your Doctor
Call your oncology team the same day if you develop a fever above 38 degrees Celsius (100.4 degrees Fahrenheit) at any point during treatment. Report any unusual bruising or bleeding, which may signal low platelet counts. Tell your team about new or worsening headaches, sudden weakness, changes in speech, or new seizures - these need prompt assessment. Before adding any supplement or over-the-counter medication during treatment, ask your oncologist first. Some medications interact with temozolomide in unexpected ways.
This article is for general information only, not medical advice. Always consult your oncologist or care team about your specific situation.